Onkolojik Acillere Yaklaşım
Synopsis
This section comprehensively covers the oncological emergencies of Superior Vena Cava Syndrome (SVCS), Hypercalcemia, and Tumor Lysis Syndrome (TLS). SVCS is a clinical condition caused primarily by lung cancer and lymphomas due to external compression or thrombosis of the SVC, manifesting with facial swelling, dyspnea, and vascular distension; its management includes head elevation, diuretics, steroids, anticoagulation, and endovaskular stenting. Hypercalcemia is defined as a serum calcium level exceeding 10.4 mg/dL, with primary hyperparathyroidism and malignancies accounting for over 90% of cases. Causing neuropsychiatric, gastrointestinal, renal, and cardiovascular symptoms, hypercalcemia treatment relies on isotonic NaCl hydration, calcitonin, bisphosphonates (zoledronic acid, pamidronate), and hemodialysis in severe cases. TLS is a metabolic emergency arising from the release of intracellular components after chemotherapy, characterized by hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia, and acute kidney failure, with hyperkalemia being the most life-threatening abnormality. Management of TLS focuses on aggressive IV hydration before and after chemotherapy, urinary alkalinization, dietary restriction of potassium and phosphate, and medical therapies including allopurinol, rasburicase, and febuxostat, with hemodialysis indicated for resistant complications and severe renal impairment.
References
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85:37.
Batts TC, Campbell CL, Roman-Gonzalez J. Superior vena cava syndrome associated with implantable cardioverter defibrillator (ICD): An uncommon complication of an increasingly common procedure: CAR-4. South Med J. 2006;99:1042.
Szokol JW, Alspach D, Mehta MK, Parilla BV, Liptay MJ. Intermittent airway obstruction and superior vena cava syndrome in a patient with an undiagnosed mediyastinal mass after cesarean delivery. Anesth Analg. 2003;97:883–4.
Higdon ML, Higdon JA. Treatment of oncologic emergencies. Am Fam Physician.2006;74:1873–80.
Yellin A, Rosen A, Reichert N,Lieberman Y. Superior vena cava syndrome. The myth-the facts. AmRev Respir Dis. 1990;141:1114-8.
Yıldızeli B. Vena kava süperior sendromu ve cerrahisi. Toraks Cerrahisi Bülteni. 2011;2: 147-158.
Minisola S, Pepe J, Piemonte S, consultant, Cipriani C, The diagnosis and management of hypercalcaemia. BMJ 2015;350:h2723.
Lafferty FW. Differential diagnosis of hypercalemia. J Bone Miner Res 1991; 6 Suppl 2:S51.
Burtis WJ, Wu TL, Insogna KL, Stewart AF. Humoral hypercalcemia of malignancy. Ann Intern Med 1988;108:454.
Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcemia. Lancet 1992; 339:164.
Wang CC, Chen YC, Shiang JC, Lin SH, Chu P, Wu CC. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med. 2009; 27: 1-3.
Pi J, Kang Y, Smith M, Earl M, Norigian Z, McBride A. A review in the treatment of oncologic emergencies. J Oncol Pharm Pract 2016;22(4):625-38
King JE. What is tumor lysis syndrome? Nursing 2008;38(5):18
Klinenberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron 1975;14(1):88-98.
Macaluso A, Genova S, Maringhini S, Coffaro G, Ziino O, D'Angelo P. Acute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia. Pediatr Rep 2015; 7(1):5760.
Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998;77 Suppl 4:18-20
Maie K, Yokoyama Y, Kurita N, et al. Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome. Springerplus 2014;3:501